[Intensive therapy in complicated forms of purulent gestational pyelonephritis].
The experience with 65 cases of purulent gestational pyelonephritis (PGP) is reviewed. The efficacy of PGP intensive therapy depends on early surgical elimination of the source of bacteriemia and sepsis. Choice of the surgical technique should be based both on extension of destructive changes in the kidney and severity of the complications. In some cases it is necessary to perform nephrostomy with sanation of the pyonecrotic foci in the kidney, in the other--it is necessary to perform urgent nephrectomy. Three basic components of pre- and postoperative intensive care should be considered: antibacterial treatment, infusion-transfusion therapy and efferent detoxication. Etiotropic therapy is conducted with three antibiotics injected intravenously and intramuscularly to provide effective concentrations of the drugs in the blood, urine and affected organs. PGP medication is based on inhibitor-defended penicillines and cephalosporines of the third-forth generation. Combined use of these antibiotics is effective in 95% cases. If the condition is life-threatening, carbapenems, fluoroguinolones, aminoglycosides and metronidasol can be applied. Detoxication is provided by 24-h infusion of crystalloids, concentrated glucose solutions (10-20%) with insulin, transfusion of fresh frozen plasm, albumin, protein. Plasmapheresis accelerates recovery, diminished nephrectomy rate by 14% and obstetric complications 1.8 fold, enables physiological term of delivery (37-39 weeks) in significant reduction of postnatal complications. Lethal outcomes were absent.
Dovlatian
A A
AA
D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D005260:Female; D006801:Humans; D009392:Nephrectomy / Q000379:methods; D010956:Plasmapheresis / Q000379:methods; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000628:therapy*; D011256:Pregnancy Outcome; D011704:Pyelonephritis / Q000628:therapy*; D012189:Retrospective Studies
D000900:Anti-Bacterial Agents